关键词: GSK Texas AM 流感疫苗
2013年3月27日讯 /生物谷BIOON/ -- GSK公司与Texas A&M公司联合投入总额高达9100万美元资金来建立一个新型流感疫苗中心。该中心将用细胞培养基取代传统的鸡胚来制备疫苗。目前美国仅有三个类似的中心在建。该中心将能够在流感爆发的四个月内生产高达5000万份流感疫苗。(生物谷Bioon.com)
详细英文报道:
As part of an ambitious effort to prep for a future pandemic, GlaxoSmithKline ($GSK) and Texas A&M are teaming up to build a $91 million flu vaccine manufacturing center in the Lone Star state that will rely on cell-culture lines rather than chicken eggs. One of only three such centers planned for the U.S., it's designed to be able to produce up to 50 million doses of a pandemic flu vaccine within four months of an outbreak. That's much faster than the old tech in use today. With typical Texan braggadocio, Governor Rick Perry said that the center would add $41 billion in new spending over 25 years while producing 6,800 direct and indirect jobs. Such figures rarely prove accurate, but who's counting in a slowpoke economy?
(责任编辑:lili.zhao)